Literature DB >> 19225843

Crossing the Rubicon: when pancreatic resection with curative intent ends in an R2 status. Impact of "desmoplastic pseudo-pancreatitis" and anatomical site of irresectability.

Maximilian Bockhorn1, Guellue Cataldegirmen, Asad Kutup, Andreas Marx, Christoph Burdelski, Jogesh K Vashist, Oliver Mann, Lena Liebl, Alexandra König, Jakob R Izbicki, Emre F Yekebas.   

Abstract

AIM: To analyze the impact of pancreatitis-mimicking, concomitant alterations on intraoperative assessment of curative resectability, the anatomical site of irresectability, and outcome after nonintentional R2 resection in pancreatic cancer.
METHODS: Of 1,099 patients subjected to pancreatic resection for cancer, 40 (4%) underwent R2 resection (group A). The site where tumors turned out to be irresectable and the coincident presence of potentially misleading, fibro-desmoplastic alterations were analyzed. Outcome after resection was compared with 40 bypass patients matched for age, gender, histopathology, and use of additive chemotherapy (group B).
RESULTS: R2 resection was due to misjudgment regarding resectability in 38 patients (95%) and to uncontrollable hemorrhage in 2 patients (5%). Group A patients had significantly longer operative times (P < 0.0001), required more blood units (P < 0.0001), and had longer hospital stay than group B patients (P = 0.049). Despite a significantly higher relaparotomy rate of 20% (n = 8) in group A versus 5% (n = 2) in group B, perioperative mortality was equal (n = 2, each). Median survival was 11.5 months in group A and 7.5 months in group B (P = 0.014). "Pancreatitis-like" lesions were assessed in 70% (n = 28/40, group A) and 25% (10/40, group B; P = 0.014). The superior mesenteric artery proximal to its jejunal branches was the most likely site of irresectability (60%), followed by its peripheral course (22.5%) and the lower aspects of the celiac trunk (17.5%).
CONCLUSIONS: Concomitant "pancreatitis-like" alterations hamper the assessment of local resectability in pancreatic cancer. Although palliative resection results in elevated perioperative morbidity compared with bypass procedures, mortality is equal, while survival is prolonged.

Entities:  

Mesh:

Year:  2009        PMID: 19225843     DOI: 10.1245/s10434-009-0363-2

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  12 in total

1.  Multivisceral resections in pancreatic cancer: identification of risk factors.

Authors:  Christoph M Burdelski; Matthias Reeh; Dean Bogoevski; Florian Gebauer; Michael Tachezy; Yogesh K Vashist; Guellue Cataldegirmen; Emre Yekebas; Jakob R Izbicki; Maximilian Bockhorn
Journal:  World J Surg       Date:  2011-12       Impact factor: 3.352

2.  Computed tomography-based diagnostics might be insufficient in the determination of pancreatic cancer unresectability.

Authors:  Vyacheslav I Egorov; Roman V Petrov; Elena N Solodinina; Gregory G Karmazanovsky; Natalia S Starostina; Natalia A Kuruschkina
Journal:  World J Gastrointest Surg       Date:  2013-04-27

3.  Management of pancreatic cancer: current status and future directions.

Authors:  H Ramesh
Journal:  Indian J Surg       Date:  2010-11-16       Impact factor: 0.656

4.  LigaSure™ vs. conventional dissection techniques in pancreatic surgery--a prospective randomised single-centre trial.

Authors:  Faik Guentac Uzunoglu; Maximilian Bockhorn; Judith Alexandra Fink; Matthias Reeh; Eik Vettorazzi; Karim Abdel Gawad; Dean Bogoevski; Yogesh Kumar Vashist; Tung Yu Tsui; Alexandra Koenig; Oliver Mann; Jakob Robert Izbicki
Journal:  J Gastrointest Surg       Date:  2012-12-19       Impact factor: 3.452

5.  Management of pancreatic cancer: Current status and future directions.

Authors:  H Ramesh
Journal:  Indian J Surg       Date:  2010-01-13       Impact factor: 0.656

6.  Bypass surgery versus intentionally incomplete resection in palliation of pancreatic cancer: is resection the lesser evil?

Authors:  Michael Tachezy; Maximilian Bockhorn; Florian Gebauer; Yogesh K Vashist; Jussuf Thomas Kaifi; Jakob Robert Izbicki
Journal:  J Gastrointest Surg       Date:  2011-02-26       Impact factor: 3.452

Review 7.  Advanced-stage pancreatic cancer: therapy options.

Authors:  Jens Werner; Stephanie E Combs; Christoph Springfeld; Werner Hartwig; Thilo Hackert; Markus W Büchler
Journal:  Nat Rev Clin Oncol       Date:  2013-04-30       Impact factor: 66.675

Review 8.  Pancreatic cancer and liver metastases: state of the art.

Authors:  Eugen Bellon; Florian Gebauer; Michael Tachezy; Jakob R Izbicki; Maximilian Bockhorn
Journal:  Updates Surg       Date:  2016-11-10

Review 9.  Surgical resection strategies for locally advanced pancreatic cancer.

Authors:  Alexander Gluth; Jens Werner; Werner Hartwig
Journal:  Langenbecks Arch Surg       Date:  2015-06-27       Impact factor: 3.445

10.  Improved survival after palliative resection of unsuspected stage IV pancreatic ductal adenocarcinoma.

Authors:  Younghwan Kim; Song Cheol Kim; Ki Byoung Song; Jayoun Kim; Dae Ryong Kang; Jae Hoon Lee; Kwang-Min Park; Young-Joo Lee
Journal:  HPB (Oxford)       Date:  2016-02-08       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.